ATANIS Biotech, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and
 
								 
								 
								 
								 
								 
								 
								 
								 
         
								 
								 
								 
								 
								 
                 
													 
													